Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
*Valneva Reports First Quarter 2024 Financial Results and *
*Provides Corporate Updates*
*Q1 financial..
*Valneva Reports First Quarter 2024 Financial Results and *
*Provides Corporate Updates*
*Q1 financial..
The RSV vaccine market size was valued at USD 1.4 Billion in 2023 and is expected to reach USD 2.2 Billion by 2032 at a CAGR of..
*Total revenues of €153.7 million, including product sales of €144.6 million*
· Product sales surpassed..